727 results Netherlands further locked in? Council of State limits internal netting of nitrogen emissions The Council of State has changed its case law on internal and external netting. This has major implications for activities involving nitrogen. In this blog Anna Collignon discusses the new case law. Waterdoelen in Nederland – een schets van de juridische stand van zaken. Het eerste blogbericht uit een reeks (deel I) Water staat hoog op de agenda. En met reden: de kwaliteit en kwantiteit van het oppervlakte- en grondwater in Nederland staan onder druk, aldus de Raad voor de leefomgeving en infrastructuur (“Rli”). If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement. The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU. The long and (un)winding road of ‘killer acquisition’ Illumina/Grail Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal. The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines. Pagination Previous page Page 38 Page 39 Page 40 Current page 41
Netherlands further locked in? Council of State limits internal netting of nitrogen emissions The Council of State has changed its case law on internal and external netting. This has major implications for activities involving nitrogen. In this blog Anna Collignon discusses the new case law.
Waterdoelen in Nederland – een schets van de juridische stand van zaken. Het eerste blogbericht uit een reeks (deel I) Water staat hoog op de agenda. En met reden: de kwaliteit en kwantiteit van het oppervlakte- en grondwater in Nederland staan onder druk, aldus de Raad voor de leefomgeving en infrastructuur (“Rli”).
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement.
The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU.
The long and (un)winding road of ‘killer acquisition’ Illumina/Grail Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal.
The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.